Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2010
12/02/2010US20100305099 Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
12/02/2010US20100305096 Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010US20100305094 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
12/02/2010US20100305093 Inhibitors of mTOR and Methods of Making and Using
12/02/2010US20100305090 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors
12/02/2010US20100305086 Pharmaceutical Compositions for the Treatment of Pain
12/02/2010US20100305084 Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010US20100305083 Substituted porphyrins
12/02/2010US20100305070 Treatment or prophylaxis of proliferative conditions
12/02/2010US20100305059 Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
12/02/2010US20100305058 Individualized cancer treatments
12/02/2010US20100305057 Synergistic pharmaceutical combination for the treatment of cancer
12/02/2010US20100305044 Peptide anti-tumor agent
12/02/2010US20100305043 Ccl18 and ccl3 methods and compositions for detecting and treating cancer
12/02/2010US20100305042 Pharmaceutical compositions and methods for the treatment of prostate cancer
12/02/2010US20100305041 Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same
12/02/2010US20100305034 Growth factor isoform
12/02/2010US20100305033 Hydroxyalkyl starch derivatives and process for their preparation
12/02/2010US20100303938 Method and preparation of herbal extract of calotropis gigantea for cancer treatment
12/02/2010US20100303929 Compounds and methods for treating cancer
12/02/2010US20100303924 Process for Producing A Beverage Comprising Cocoa Material with Enhanced Polyphenol Levels
12/02/2010US20100303922 Method for the preparation of biocompatible polymeric nanoparticles for drug delivery and nanoparticles prepared thereby
12/02/2010US20100303912 Nanocell Drug Delivery System
12/02/2010US20100303904 Tablet with remedial composition and methods for treating medical disorders and ailments
12/02/2010US20100303899 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
12/02/2010US20100303896 5beta, 14beta-androstane derivatives useful for the treatment of restenosis after angioplastic or endoartherectomy and diseases due to organ fibrosis
12/02/2010US20100303895 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
12/02/2010US20100303893 Novel compound for treatment of tumor
12/02/2010US20100303878 Biodegradable bioactive agent releasing matrices with particulates
12/02/2010US20100303870 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
12/02/2010US20100303856 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
12/02/2010US20100303851 Immunostimulation by chemically modified rna
12/02/2010US20100303850 Nanocarriers possessing components with different rates of release
12/02/2010US20100303841 Adjuvant
12/02/2010US20100303839 Methods and compositions for treatment of cancer using oncolytic rsv activity
12/02/2010US20100303838 Vectors for multiple gene expression
12/02/2010US20100303836 Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
12/02/2010US20100303834 Compositions and methods for the diagnosis and treatment of tumor
12/02/2010US20100303833 Method for Identifying a MHC Class H-Dependent Tumor Associated T Helper Cell Antigen
12/02/2010US20100303828 Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
12/02/2010US20100303826 Use of ADCC-Optimized antibodies for treating weak patients
12/02/2010US20100303823 Human monoclonal antibodies against interleukin 8 (il-8)
12/02/2010US20100303821 Immunoglobulins
12/02/2010US20100303819 Dcl-1 and uses thereof
12/02/2010US20100303817 Antibodies to treat cancer
12/02/2010US20100303816 Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (mcsp)
12/02/2010US20100303814 Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof
12/02/2010US20100303812 Neutralizing monoclonal antibody against human dll4
12/02/2010US20100303809 Methods for the detection and quantitation of pten
12/02/2010US20100303803 Catenate for immunostimulation
12/02/2010US20100303795 Marker of prostate cancer
12/02/2010US20100303793 Combination therapy for cardiac revascularization and cardiac repair
12/02/2010US20100303779 Non-Conventional NKT Cells for Use in Cancer Therapy
12/02/2010US20100303766 Cell population with enhanced transplantation activity
12/02/2010US20100303759 polynucleotide encoding a protein that is non-naturally occurring and has enhanced anti-viral and anti-proliferative activity in comparison to human interferon alpha 2b (HuIFN- alpha 2b); treating cancer responsive to interferon alpha therapy
12/02/2010US20100303754 Process for preparation of cyclodextrin oligomers or polymers, products obtained and uses
12/02/2010US20100303730 Methods of making iron-containing nanoparticles
12/02/2010US20100303726 Humanized collagen antibodies and related methods
12/02/2010US20100303720 VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49
12/02/2010US20100303719 Anti-cancer compounds
12/02/2010US20100303718 Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials
12/02/2010US20100303717 Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials Cross Reference to Related Applications
12/02/2010US20100303715 Prostate-specific membrane antigen and uses thereof
12/02/2010US20100303714 Oncolytic vaccinia virus cancer therapy
12/02/2010DE102009022895A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022892A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022794A1 Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel Use of inhibitors of HAT and TMPRSS2 as drugs
12/02/2010CA2763950A1 Use of 2 anti-sparc antibodies to predict response to chemotherapy
12/02/2010CA2763700A1 2, 4-diamino pyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
12/02/2010CA2763631A1 Pyrimidine inhibitors of kinase activity
12/02/2010CA2763624A1 Pyrimidine inhibitors of kinase activity
12/02/2010CA2763614A1 Iap inhibitors
12/02/2010CA2763589A1 N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
12/02/2010CA2763488A1 Antigen-binding proteins
12/02/2010CA2763486A1 Casb7439 constructs
12/02/2010CA2763485A1 Methods for treating cancer and non-neoplastic conditions
12/02/2010CA2763471A1 Combination therapy for the treatment of multiple myeloma
12/02/2010CA2763381A1 Substituted piperidines
12/02/2010CA2763365A1 Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
12/02/2010CA2763351A1 Substituted 3-(1,2,4-oxadiazol-5-yl)-5-phenylpiperidines
12/02/2010CA2763275A1 Continuous administration of integrin ligands for treating cancer
12/02/2010CA2763041A1 Compositions and methods for modulating lipid composition
12/02/2010CA2763008A1 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
12/02/2010CA2762934A1 Cdc45l peptides and vaccines including the same
12/02/2010CA2762877A1 Polyal drug conjugates comprising variable rate-releasing linkers
12/02/2010CA2762479A1 Inhibitors of c-met protein kinase
12/02/2010CA2762303A1 Differentiation therapy for sarcomas
12/02/2010CA2762190A1 Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
12/02/2010CA2762186A1 Substituted pyrazole inhibitors of c-met protein kinase
12/02/2010CA2761639A1 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
12/02/2010CA2761445A1 Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010CA2759182A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/01/2010EP2256201A2 Modulation of eIF4E expression
12/01/2010EP2256200A2 Modulation of eIF4E expression
12/01/2010EP2256199A1 Therapeutic uses of BR43X2 soluble receptors
12/01/2010EP2256118A1 Condensed imidazolo derivatives for the inhibition of aromatase
12/01/2010EP2256109A1 Apoptosis inhibitor
12/01/2010EP2256108A1 Substituted triazine kinase inhibitors
12/01/2010EP2256106A1 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
12/01/2010EP2255830A1 Concomitant drug
1 ... 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 ... 2211